Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04179175 · ClinicalTrials.gov registry record · Phase 3
Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa
A Phase 3 study of Hidradenitis Suppurativa, sponsored by Novartis Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 703
- Enrollment target
- 20
- Study locations
NCT04179175 is a Phase 3 study of Hidradenitis Suppurativa that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 703 participants, above the 585-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (20% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT04179175, a Phase 3 study of Hidradenitis Suppurativa, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 703 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this extension study is to evaluate maintenance of Hidradenitis Suppurativa Clinical Response (HiSCR response) in either continuous or interrupted therapy (using a randomized withdrawal period) of two dose regimens and to assess long-term efficacy, safety and tolerability of Secukinumab in subjects with moderate to severe hidradenitis suppurativa completing either of the 2 Phase III studies. This is an expanded access trial for the core trials CAIN457M2301 (NCT03713619) and CAIN457M2302 (NCT03713619).
Conditions Studied
Interventions
- DRUG secukinumab
Study Locations (20)
Florida
- Florida Academic Centers Research and Education LLC - Coral Gables
- University of MiamiHealth System - Miami
- Olympian Clinical Research - Tampa
- University Of South Florida - Tampa
California
- MedDerm Associates - San Diego
- University Clinical Trials - San Diego
- Southern California Skin and Laser - Whittier
Missouri
- MediSearch Clinical Trials - Saint Joseph
- St Louis U Clinical Trials - St Louis
- WA Uni School Of Med - St Louis
Illinois
- Endeavor Health - Glenview
- Dundee Dermatology - West Dundee
Massachusetts
- Tufts Medical Center - Boston
- Beth Israel Deaconess Med Center - Boston
Arkansas
- Northwest Arkansas Center - Rogers
Georgia
- Advanced Medical Research - Sandy Springs
Indiana
- Dawes Fretzin Clinical Rea Group - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 703 participants |
| Start Date | 2020-03-18 |
| Est. Completion | 2026-07-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04179175
The ClinicalTrials.gov registry entry for NCT04179175 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 703 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 585-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (20% higher). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 1 intervention - of which secukinumab is the first listed.
NCT04179175 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, California, Missouri.
Frequently Asked Questions
What is clinical trial NCT04179175 about?
NCT04179175 is a clinical study titled "Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa". The purpose of this extension study is to evaluate maintenance of Hidradenitis Suppurativa Clinical Response (HiSCR response) in either continuous or interrupted therapy (using a randomized withdrawal period) of two dose regimens and to assess long-term efficacy, safety and tolerability of Secukinum...
What is the current status of trial NCT04179175?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 703 participants. The study started on 2020-03-18. Estimated completion is 2026-07-15.
What conditions does trial NCT04179175 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa.
What interventions are being tested in trial NCT04179175?
The interventions under investigation include: secukinumab (DRUG).
Who is sponsoring clinical trial NCT04179175?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04179175 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
RECRUITING · Phase 3
-
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 3
-
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 3
-
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
RECRUITING · Phase 3
-
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
RECRUITING · Phase 3
-
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.